Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + oxaliplatin + bevacizumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A four-drug oncology regimen combining the oral fluoropyrimidine prodrug capecitabine, the platinum agent oxaliplatin, and two monoclonal antibodies—bevacizumab (anti-VEGF) and trastuzumab (anti-HER2). Mechanistically, it integrates cytotoxic chemotherapy (DNA damage and thymidylate synthase inhibition) with targeted anti-angiogenic therapy and HER2 blockade. Clinically, XELOX/CAPOX plus bevacizumab is established for metastatic colorectal cancer, while bevacizumab plus trastuzumab with capecitabine or taxanes has been studied in HER2-positive metastatic breast cancer. This specific four-drug combination is used off-label in selected HER2-positive, HER2-expressing, or mixed histology gastrointestinal malignancies in practice and exploratory settings; there is no unique brand name for the combination.
- Other names
- XELOX plus bevacizumab plus trastuzumabCAPOX plus bevacizumab plus trastuzumabcapecitabine + oxaliplatin + bevacizumab + HER2 antibody
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + oxaliplatin + bevacizumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + oxaliplatin + bevacizumab + trastuzumab.